Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ATRC logo ATRC
Upturn stock ratingUpturn stock rating
ATRC logo

AtriCure Inc (ATRC)

Upturn stock ratingUpturn stock rating
$32.77
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ATRC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $49.89

1 Year Target Price $49.89

Analysts Price Target For last 52 week
$49.89Target price
Low$20.2
Current$32.77
high$43.11

Analysis of Past Performance

Type Stock
Historic Profit -29.68%
Avg. Invested days 33
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.60B USD
Price to earnings Ratio -
1Y Target Price 49.89
Price to earnings Ratio -
1Y Target Price 49.89
Volume (30-day avg) 9
Beta 1.6
52 Weeks Range 20.20 - 43.11
Updated Date 06/29/2025
52 Weeks Range 20.20 - 43.11
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.81

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -7.95%
Operating Margin (TTM) -4.82%

Management Effectiveness

Return on Assets (TTM) -3.7%
Return on Equity (TTM) -8.38%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1575544590
Price to Sales(TTM) 3.33
Enterprise Value 1575544590
Price to Sales(TTM) 3.33
Enterprise Value to Revenue 3.28
Enterprise Value to EBITDA -135.97
Shares Outstanding 49504900
Shares Floating 47729112
Shares Outstanding 49504900
Shares Floating 47729112
Percent Insiders 3.37
Percent Institutions 103.63

Analyst Ratings

Rating 3
Target Price 49.89
Buy 4
Strong Buy 5
Buy 4
Strong Buy 5
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

AtriCure Inc

stock logo

Company Overview

overview logo History and Background

AtriCure, Inc. was founded in 2000. It is a medical device company focusing on developing, manufacturing, and selling innovative solutions for the treatment of atrial fibrillation and related conditions.

business area logo Core Business Areas

  • Ablation Systems: Develops and markets radiofrequency (RF) ablation devices used to create lesions on heart tissue to treat atrial fibrillation.
  • Left Atrial Appendage Management: Offers devices for occluding or excising the left atrial appendage (LAA) to reduce the risk of stroke in patients with atrial fibrillation.
  • Open Heart Surgery: Also sells products for open heart surgery.

leadership logo Leadership and Structure

Michael Carrel serves as the President and Chief Executive Officer. The company has a typical corporate structure with a board of directors and various functional departments.

Top Products and Market Share

overview logo Key Offerings

  • CryoICE Cryoablation System: A cryoablation system used to create lesions on the heart. It competes with Medtronic, Boston Scientific, and Abbott. Market Share data is not publically available per product.
  • AtriClip LAA Exclusion System: A clip used to occlude the left atrial appendage. This is a primary product, but specifics of market share and revenue are not publicly available. Competitors include Boston Scientific and Johnson & Johnson.

Market Dynamics

industry overview logo Industry Overview

The electrophysiology (EP) market is experiencing growth due to the increasing prevalence of atrial fibrillation and advancements in ablation technologies. The cardiac surgery market is also a large market and Atricure competes in different areas here.

Positioning

AtriCure is a key player in the atrial fibrillation ablation and left atrial appendage management market, known for its innovative ablation technologies and LAA exclusion devices. Their competitive advantage includes a focus on minimally invasive surgical approaches.

Total Addressable Market (TAM)

The total addressable market for AtriCure is estimated to be in the billions of dollars, encompassing atrial fibrillation ablation, LAA management, and pain management. AtriCure is positioned to capture a significant share of this market through its innovative products and focus on minimally invasive procedures.

Upturn SWOT Analysis

Strengths

  • Innovative product portfolio
  • Strong presence in the atrial fibrillation market
  • Focus on minimally invasive procedures
  • Established distribution network

Weaknesses

  • Reliance on specific product lines
  • Potential for product recalls
  • Competition from larger medical device companies

Opportunities

  • Expanding into new geographic markets
  • Developing new products for related cardiac conditions
  • Acquiring complementary technologies or businesses

Threats

  • Increased competition from established players
  • Changes in healthcare regulations
  • Pricing pressures from hospitals and payers
  • Technological obsolescence

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • ABT
  • BSX
  • JNJ

Competitive Landscape

AtriCure competes with larger medical device companies with greater resources. AtriCure's advantage lies in its focus on specific areas of cardiac surgery and innovative product development.

Major Acquisitions

Estech Systems, Inc.

  • Year: 2017
  • Acquisition Price (USD millions): 36
  • Strategic Rationale: Expand AtriCure's product portfolio in cardiac ablation technologies.

Growth Trajectory and Initiatives

Historical Growth: AtriCure has experienced growth driven by adoption of its ablation and LAA management products.

Future Projections: Future growth is projected based on continued adoption of existing products and the introduction of new innovations. Consult analyst reports for specific estimates.

Recent Initiatives: Recent initiatives include expanding clinical trials for new applications of their products and strategic partnerships.

Summary

AtriCure is a moderately strong company in the cardiac ablation and LAA management market. Its innovative product portfolio is a key strength, but it faces competition from larger players. Expanding geographically and developing new products offer significant growth opportunities while healthcare regulations and pricing pressures pose potential threats.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings, analyst reports, industry publications, press releases

Disclaimers:

This analysis is based on publicly available information and should not be considered financial advice. Market share data is estimated.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About AtriCure Inc

Exchange NASDAQ
Headquaters Mason, OH, United States
IPO Launch date 2005-08-05
CEO, President & Director Mr. Michael H. Carrel
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 1300
Full time employees 1300

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.